Symbol="VOR"
AssetType="Common Stock"
Name="Vor Biopharma Inc"
Description="Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts."
CIK="1817229"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="100 CAMBRIDGEPARK DRIVE, SUITE 101, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="188149000"
EBITDA="-98104000"
PERatio="None"
PEGRatio="None"
BookValue="3.439"
DividendPerShare="0"
DividendYield="0"
EPS="-1.85"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.247"
ReturnOnEquityTTM="-0.461"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.85"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="14.81"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.579"
EVToRevenue="-"
EVToEBITDA="-1.827"
Beta="-0.872"
num_52WeekHigh="7.57"
num_52WeekLow="2.63"
num_50DayMovingAverage="4.062"
num_200DayMovingAverage="4.866"
SharesOutstanding="66957000"
DividendDate="None"
ExDividendDate="None"
symbol="VOR"
open="2.92"
high="2.97"
low="2.78"
price="2.81"
volume="94698.00"
latest_trading_day="2023-07-27"
previous_close="2.90"
change="-0.09"
change_percent="-3.1034%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="193451"
Change_recent_avg="-0.04"
Delta_recent_avg="0.35"
Variance_recent_avg="0.18"
Change_ratio_recent_avg="-1.11"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="505"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0100.jpeg"
image_negative_thumbnail_id_2="1148"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0181.jpeg"
image_neutral_thumbnail_id_1="588"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0011.jpeg"
image_neutral_thumbnail_id_2="535"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0064.jpeg"
image_positive_thumbnail_id_1="985"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0147.jpeg"
image_positive_thumbnail_id_2="970"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0132.jpeg"
image_professor_thumbnail_id_1="1178"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
